Rodney U. Anderson

发表

Equal Improvement in Men and Women in the Treatment of Urologic Chronic Pelvic Pain Syndrome Using a Multi-modal Protocol with an Internal Myofascial Trigger Point Wand

B. Nathanson, T. Sawyer, D. Wise, 2015, Applied Psychophysiology and Biofeedback.

Category III chronic prostatitis/chronic pelvic pain syndrome: Insights from the national institutes of health chronic prostatitis collaborative research network studies

M. Pontari, A. Schaeffer, M. Litwin, 2007, Current urology reports.

Randomized multicenter feasibility trial of myofascial physical therapy for the treatment of urological chronic pelvic pain syndromes.

S. Chuai, J. Kusek, J. Landis, 2009, The Journal of urology.

Randomized multicenter feasibility trial of myofascial physical therapy for the treatment of urological chronic pelvic pain syndromes.

S. Chuai, J. Kusek, J. Landis, 2009, The Journal of urology.

Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles: a subanalysis of data from the OPERA trial.

R. Dmochowski, P. Sand, D. Lama, 2005, American journal of obstetrics and gynecology.

Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder

R. Goldberg, S. Kell, S. Macdiarmid, 2006, International Urogynecology Journal.

Efficacy and safety of extended release oxybutynin for the treatment of urge incontinence: an analysis of data from 3 flexible dosing studies.

R. Armstrong, R. Dmochowski, S. Macdiarmid, 2005, The Journal of urology.

Effect of controlled‐release delivery on the pharmacokinetics of oxybutynin at different dosages: severity‐dependent treatment of the overactive bladder

C. Hampel, D. Albrecht, M. Preik, 2004, BJU international.

Pharmacotherapy for Neurogenic Detrusor Overactivity

M. Chancellor, T. Boone, Rodney U Anderson, 2006, American journal of physical medicine & rehabilitation.

6-day intensive treatment protocol for refractory chronic prostatitis/chronic pelvic pain syndrome using myofascial release and paradoxical relaxation training.

E. Orenberg, P. Glowe, T. Sawyer, 2011, The Journal of urology.

Feasibility Trial of Medical Hypnosis and Cognitive Behavioral Therapy for Men With Refractory Chronic Prostatitis/Chronic Pelvic Pain Syndrome

E. Orenberg, P. Glowe, Angie Morey, 2011 .

Painful myofascial trigger points and pain sites in men with chronic prostatitis/chronic pelvic pain syndrome.

B. Nathanson, T. Sawyer, Rodney U Anderson, 2009, The Journal of urology.

Chapter 91 – FOCAL NEUROMUSCULAR THERAPIES FOR CHRONIC PELVIC PAIN SYNDROMES IN WOMEN

Rodney U. Anderson, 2008 .

Traditional therapy for chronic pelvic pain does not work: what do we do now?

Rodney U. Anderson, 2006, Nature Clinical Practice Urology.

Integration of myofascial trigger point release and paradoxical relaxation training treatment of chronic pelvic pain in men.

T. Sawyer, Rodney U Anderson, C. Chan, 2005, The Journal of urology.

ORIGINAL RESEARCH—PSYCHOLOGY: Integrated Sildenafil and Cognitive‐Behavior Sex Therapy for Psychogenic Erectile Dysfunction: A Pilot Study

L. Banner, Rodney U. Anderson, Linda L. Banner, 2007 .

Sexual dysfunction in men with chronic prostatitis/chronic pelvic pain syndrome: improvement after trigger point release and paradoxical relaxation training.

T. Sawyer, C. Chan, D. Wise, 2006, The Journal of urology.

Alfuzosin and symptoms of chronic prostatitis-chronic pelvic pain syndrome.

M. Pontari, A. Schaeffer, M. Litwin, 2008, The New England journal of medicine.

A RANDOMIZED PLACEBO-CONTROLLED MULTICENTER TRIAL OF PREGABALIN FOR THE TREATMENT OF MEN WITH CHRONIC PROSTATITIS/CHRONIC PELVIC PAIN SYNDROME

M. Pontari, A. Schaeffer, M. Litwin, 2009 .

Chronic Prostatitis and/or Chronic Pelvic Pain as a Psychoneuromuscular Disorder-A Meta-analysis.

B. Nathanson, Rodney U Anderson, D. Wise, 2018, Urology.

Psychometric profiles and hypothalamic-pituitary-adrenal axis function in men with chronic prostatitis/chronic pelvic pain syndrome.

E. Orenberg, Rodney U Anderson, C. Chan, 2008, The Journal of urology.

The role of pelvic floor therapies in chronic pelvic pain syndromes

Rodney U. Anderson, 2008 .

The Assessment and Management of Male Pelvic Pain Syndrome, Including Prostatitis (Part I)

A. Schaeffer, J. Krieger, L. Nyberg, 2006 .

Pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome: a randomized controlled trial.

M. Pontari, A. Schaeffer, M. Litwin, 2010, Archives of internal medicine.

Management of chronic prostatitis-chronic pelvic pain syndrome.

Rodney U. Anderson, 2002, The Urologic clinics of North America.

Sacral nerve stimulator revision due to somatic growth.

W. Kennedy, C. Comiter, Tin C. Ngo, 2011, The Journal of urology.

OnabotulinumtoxinA office treatment for neurogenic bladder incontinence in Parkinson's disease.

E. Orenberg, P. Glowe, Rodney U. Anderson, 2014, Urology.

MYOFASCIAL RELEASE THERAPY FOR CATEGORY III CHRONIC PROSTATITIS

D. Wise, Rodney U. Anderson, M. Meadows, 1999 .

Stress induced hypothalamus-pituitary-adrenal axis responses and disturbances in psychological profiles in men with chronic prostatitis/chronic pelvic pain syndrome.

E. Orenberg, C. Chan, Angie Morey, 2009, The Journal of urology.

Equal Improvement in Men and Women in the Treatment of Urologic Chronic Pelvic Pain Syndrome Using a Multi-modal Protocol with an Internal Myofascial Trigger Point Wand

B. Nathanson, T. Sawyer, Rodney U Anderson, 2016, Applied psychophysiology and biofeedback.

Pain: Drug therapies for CP/CPPS: help or hype?

B. Nathanson, Rodney U Anderson, Rodney U. Anderson, 2011, Nature Reviews Urology.

Chronic Pelvic Pain Syndrome: Reduction of Medication Use After Pelvic Floor Physical Therapy with an Internal Myofascial Trigger Point Wand

B. Nathanson, Richard H. Harvey, T. Sawyer, 2015, Applied Psychophysiology and Biofeedback.

Chronic Pelvic Pain Syndrome: Reduction of Medication Use After Pelvic Floor Physical Therapy with an Internal Myofascial Trigger Point Wand

B. Nathanson, Richard H. Harvey, T. Sawyer, 2015, Applied psychophysiology and biofeedback.

Current Research and Investigational Procedures in Neurogenic Bladder

Rodney U. Anderson, 1993 .

Safety and Effectiveness of an Internal Pelvic Myofascial Trigger Point Wand for Urologic Chronic Pelvic Pain Syndrome

B. Nathanson, T. Sawyer, D. Wise, 2011, The Clinical journal of pain.

Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study.

R. Dmochowski, D. Staskin, N. Zinner, 2001, Mayo Clinic proceedings.

Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group.

J. Susset, Jeanette S. Brown, D. Saltzstein, 1999, The Journal of urology.

Functional and urodynamic characteristics of an ileal neobladder.

F. Freiha, H. Gill, H. Gill, 1993, The Journal of urology.

6-day intensive treatment protocol for refractory chronic prostatitis/chronic pelvic pain syndrome using myofascial release and paradoxical relaxation training.

E. Orenberg, T. Sawyer, D. Wise, 2011, The Journal of urology.

Alfuzosin and symptoms of chronic prostatitis-chronic pelvic pain syndrome.

M. Pontari, A. Schaeffer, M. Litwin, 2008, The New England journal of medicine.